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Available online 21 January 2016To permit appropriate targeted therapy, the present clinical studywas aimed to investigate the effects of proges-
terone on the outcome and the serum markers of injury, oxidant activity and inﬂammation in diffuse axonal in-
jury (DAI). Forty-eightmaleDAI patientswere divided into two groups (control and progesterone). Progesterone
group received progesterone in dose of 1 mg/kg per 12 h for ﬁve days. The outcome was investigated using
Extended Glasgow Outcome Scale (GOS-E) and functional independence measure (FIM). The markers of inﬂam-
mation [interleukin-1β (IL-1β), IL-6, transforming growth factor-β1 (TGF-β1)], injury (brain protein of S-100B),
and oxidant activity [malondialdehyde (MDA)] were evaluated in the serum of the patients. Higher GOS-E and
FIM scoreswere observed in progesterone group at the six-month follow-up (P b 0.05 and P b 0.01, respectively).
Meanwhile, a reduction in the serum levels of IL-1β, MDA and S-100B was noticed in progesterone group 24 h
after injury (P b 0.05, P b 0.001 and P b 0.05, respectively), and there was an increase in serum levels of IL-6
and TGF-β1 (P b 0.01 and P b 0.05, respectively). Also, lower levels of MDA and S-100B, and higher levels of
TGF-β1were observed in progesterone group six days after injury (P b 0.05). According to theseﬁndings, proges-
teronemay improve the outcome in DAI patients probably throughmodulation in the levels of cytokines, and re-
duction in the injury and oxidant activity.
© 2016 Elsevier B.V. All rights reserved.Keywords:
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Traumatic brain injury (TBI) is a leading cause of death and severe
disability around the world and results in large direct and indirect
costs to society. Diffuse axonal injury (DAI) is one of the most common
types of TBI, and accounts for about half of severe TBIs [1]. Although the
clinical management of TBI has been greatly improved for the develop-
ment of standards of care, no medical treatment has been proven to be
effective in reducing death or disability following TBI [2].
TBI results in both primary brain injury immediately caused by an
initial impact and secondary brain injury caused by cellular and molec-
ular responses to a primary injury. These responses comprise releasing
free radicals, neuroinﬂammation and apoptosis leading to brain
edema and delayed neuronal death which are considered to worsen a
primary brain injury and to inﬂuence the neurologic outcome ofpatients [3,4]. Therefore, major opportunity for interventions to limit
neurological defect is reversing or preventing a secondary brain injury
[5].
As secondary brain injury mechanisms are complex and various, si-
multaneous targeting of several injury factors using multipotential
drugs may improve the outcome of TBI patients [6]. After three decades
of extensive research on progesterone in TBI, it is known that this
neurosteroid affects multiple mechanisms involved in neuroprotection
and repair after various types of brain injury [7,8]. Although the clinical
beneﬁt of progesterone has been suggested in three phase II random-
ized controlled clinical trials for TBI patients [9–11], two phase III clinical
trials have not displayed the efﬁcacy of progesterone in TBI [12,13]. The
adverse events attributable to progesterone drug have not been report-
ed in TBI patients [10,11].
It seems that TBI studies should be focused on the molecular mech-
anisms of injury, rather than merely clinical observations. In recent
years, TBI studies have been concentrated on whether brain-derived
substances detectable in biological ﬂuids could be useful as efﬁcacy
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disruption causes either entering of peripheral proteins into cerebrospi-
nal ﬂuid (CSF) or leakage of CSF proteins that both can provide bio-
markers of TBI [15]. Accordingly, S-100B is best known as a CSF/serum
marker of injury in TBI [16,17], and is a calcium-binding protein physi-
ologically produced and released by astrocytes in central nervous sys-
tem (CNS) [18]. The concentration of this protein increases in CSF and
serum following cerebral injuries [19], and can be useful as a serum bio-
marker of injury in DAI patients [20,21]. Malondialdehyde (MDA) is a
noxious product of lipid peroxidation due to acting reactive oxygen spe-
cies (ROS) which increase BBB permeability in TBI [22], moreover stud-
ies have reported a considerable increase in the production of ROS in TBI
[23,24]. Because of short half-life of ROS, products of acting ROS includ-
ingMDA are used for the estimation of ROS [25]. Damage to brainmem-
brane lipids is an early event in brain injury [26]. An increase in brain
levels of cytokines in patientswith brain injury also causes neuroinﬂam-
mation and damage of BBB leading to the releasing of cytokines into sys-
temic blood circulation [3,27].
Progesterone reduces lipid peroxidation leading to themaintenance
ofmembrane integrity and stabilization of BBB in experimental brain in-
jury that improves the outcome [28–31]. Moreover, progesterone sup-
presses inﬂammation in preclinical models of TBI by modulating
cytokine release and by inhibiting immune cell activation andmigration
[32–34]. Also, it has been previously indicated that progesterone re-
duces brain edema and BBB permeability following experimental TBI
[35], and these effects were associated with reducing interleukin-1β
(IL-1β), TNFα, IL-6 and increasing transforming growth factor-β1
(TGF-β1) in the brain [36,37].
Since the results of the performed clinical trials of progesterone in
TBI are paradoxical, the effect of progesterone on the neurological out-
come of DAI patients remains unknown [9–13]. Also, TBI biomarkers
can indicate appropriate therapeutic strategies to minimize secondary
brain injury and improve the development of individualized treatment,
thereby reducing poor outcome [38]. Thus, considering the above, we
designed a clinical trial to determine the effects of the early administra-
tion of progesterone on the outcome, and injury, oxidant activity andFig. 1. Diagram of the phases of a parallel randomized trial for two groups of DAI patients (inﬂammation markers in moderate and severe DAI patients. To this
end, ﬁrstly, the outcome was assessed using Extended-Glasgow Out-
come Scale (GOS-E) and functional independence measure (FIM) at a
three- and six-month follow-up. Secondly, injury (S-100B), oxidant ac-
tivity (MDA) and inﬂammation (IL-1β, IL-6 and TGF-β1) markers were
evaluated using serum collection at the time of admission, and 24 h and
six days after injury.2. Materials and methods
2.1. Patients and study design
The study conducting and reporting were according to Good Clinical
Practice and CONSORT Guidelines [39] (Fig. 1). The study protocol was
approved by ethics committee of KermanUniversity ofMedical Sciences
(K/92/579) and registered in Iranian Registry of Clinical Trials (www.
irct.ir, CT2014042017356N1). This prospective, single-blind study was
performed in the traumamain center of Kerman province, called Shahid
Bahonar Hospital from May 2013 to July 2015.
The male patients with a non-penetrating TBI were selected on the
basis of eligibility and exclusion criteria by a physician that was not in-
formed to study design. The eligibility criteriawere GlasgowComa Scale
(GCS) score of 12 or less, DAI using computed tomography (CT) scan,
admission within four hours after injury, and 18 to 60 years of age.
The exclusion criteria were a life expectancy of less than 24 h, a
prolonged hypoxemia (partial pressure of arterial oxygen,
b60 mmHg), hypotension (systolic blood pressure, b90 mmHg), selec-
tion for surgery, craniotomy, presence of other diseases and spinal
cord injury at the time of randomization, and other traumas during
DAI. An informed consent was taken from the patients' relatives.
In the current study, forty-eightmale patients whowere selected on
the basis of eligibility and exclusion criteria were randomly placed in
case (received progesterone) or control (DAI) groups. The sample size
was estimated by PASS and NCSS software using values from relevant
studies [11]. Randomization was performed using random digitstudy enrollment, randomization, follow-up, and data analysis). n: number of patients.
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[11].
Blood samples were drawn at three time points (3 mL of blood in
each time) from all the patients. To obtain the value of serum markers
in time of injury, a blood sample was drawn at the time of admission.
The second and third blood samples were drawn at times of 24 h and
six days after injury, respectively. We performed the evaluation of
serum markers at times of 24 h and six days after injury because it has
been shown that activation of the inﬂammatory cascade in injured
area does not reach its peak before 24 h in TBI [40] and also, because
of the period of progesterone administration. The blood samples were
centrifuged at 4000 g for 10 min to collect serum. The serum markers
that were index of injury (S-100B), oxidant activity (MDA), and inﬂam-
mation (IL-1β, IL-6 and TGF-β1)were evaluated in the present research
by an experimenter who was blind to the samples of the study.
GOS-E and FIM were assessed at three and six months after injury.
GCS, body temperature, heart rate, respiratory rate, blood pressure,
and blood oxygen saturation were recorded during stay in hospital.
And, laboratory tests including hematology, coagulation proﬁle and bio-
chemistry were performed daily until one week after injury.
Progesterone (Aboureihan Pharmaceutical Company, Iran) in case
group was received intramuscularly 1 mg/kg every 12 h, for ﬁve days
[11], and all of the study patients received standard clinical manage-
ment protocol for TBI [41]. The adverse events of progesterone adminis-
tration were checked in progesterone group according to Table 1.
2.2. Evaluation of outcomes
The primary outcome was analyzed according to GOS-E and FIM
scores six months after injury. A GOS-E score of 1 indicates death, 2 in-
dicates a vegetative state, 3 or 4 indicates a severe disability, 5 or 6 indi-
cates amoderate disability, and 7 or 8 indicates a good recovery [42]. An
FIM score is a measure of dependence in 18 domains (13 motor and 5
cognitive) [43]. Motor domains are scaled 1 to 7, except two domains
(sphincters control) that are scaled 1 to 2. Cognitive domains are scaled
1 to 3, except two domains (conception and expression) that are scaled
1 to 6. The minimum FIM score is 18, and the maximum is 102.
The secondary outcome was assessed using GOS-E and FIM scores
three months after injury. A GOS-E useful score shows an evaluation
of function and dependence, and an FIM score determines cognitive
function, motor function, and daily activities [11]. Thus, in the present
study, the functional outcome was evaluated using GOS-E and FIM
scores.
2.3. Determination of serum level of MDA
MDA is a well-known indicator of lipid peroxidation, and its level
was obtained using the thiobarbituric acid method [44] and using a
standard curve prepared by tetramethoxypropane. Brieﬂy, the serum
was precipitated by 10% trichloroacetic acid (TCA), and the pink color
resulting from thiobarbituric acid reaction, as index of lipid peroxida-
tion, was measured at 535 nm [31]. The level of MDA was expressed
as micromoles per milliliter (μmol/mL).
2.4. Assay of serum levels of cytokines (IL-1β, IL-6 and TGF-β1)
Enzyme-linked immunosorbent assay (ELISA) kits of IL-1β (sensitiv-
ity range: 3.91–250 pg/mL), IL-6 (sensitivity range: 9.38–600 pg/mL),Table 1
Adverse events checked in progesterone-administered patients with DAI.
Thromboembolism
Deep vein thrombosis (DVT)
Pulmonary thromboembolism (PTE)
Blood pressureand TGF-β1 (sensitivity range: 31.3–2000 pg/mL) relevant to human
were purchased (DuoSet ELISA Development System, R&D Systems,
Minneapolis, USA) and the manufacturer's protocols were followed.
The serum levels of cytokines in all the samples were assessed in tripli-
cate. Intra- and inter-assay precision tests were also performed, and the
accuracy of these kitswasquantiﬁed by recovery experiments. Itwas in-
dicated that about 90%–98% of a recombinant human cytokine standard
can be determined. The serum levels of IL-1β and IL-6 were quantiﬁed
as picograms of antigen per milliliter of serum (pg/mL), and TGF-β1 as
nanograms of antigen per milliliter of serum (ng/mL).
2.5. Assay of serum level of brain protein (S-100B)
The serum level of S100B protein was measured by a commercially
human S-100B ELISA kit (sensitivity range 41–2000 pg/mL)
((BioVendor, Brno, Czech Republic). A quantitative assay was done
using the secondary antibody labeled with peroxidase. After adding a
peroxidase substrate to microplate, a colored product was produced to
read in a spectrophotometer. The serum level of S-100B was expressed
as picograms per milliliter (pg/mL).
2.6. Determination of serum level of progesterone
The serum level of progesterone was measured using human pro-
gesterone ELISA kit (Ideal Tashkhis, Iran) (sensitivity range:
0–60 ng/mL) according to the manufacturer's protocol. Inter- and
intra-assay coefﬁcients of variations were 9 and 5.7%, respectively.
2.7. Statistical analysis
The datawere expressed asmean± SEM, or frequency and percent-
age. The data normality was checked by Shapiro–Wilk's test. There was
normal distribution only for variables of TGF-β1, MDA, S100 and GOS.
But all of the quantitative variables were expressed as mean ± SEM
for simplicity and clarity. A mixed design analysis of variance
(ANOVA) was performed to evaluate an interaction between the times
of the variables and the groups. The comparison of the variables
among the times was analyzed using Friedman test and two way re-
peated measures ANOVA after checking normality. When sphericity
was violated, Greenhouse–Geisser correction was used (interaction be-
tween groups and times, P b 0.001). Therefore, this comparison was an-
alyzed by paired t-test or Wilcoxon test according to normality. The
comparison between the groups for the quantitative variables was per-
formed by two independent-tests or Mann–Whitney-U-test after
checking normality. And, the qualitative variables between the groups
were compared by Chi-square test or Fisher's exact test after checking
normality. At P ≤0.05, the difference was considered signiﬁcant.
3. Results
3.1. Study patients
A total of 279male patients with non-penetrating TBI were screened
during the study. And, the patients (n = 48) meeting the eligibility
criteria were randomly placed in progesterone (n = 24) or control
(n = 24) group. The patients who stayed in the hospital for less than
six days were excluded from the study due to their unavailability
(25%). Also, four patients (8.33%) who were in progesterone group
withdrew from the trial before the completion of the drug administra-
tion period. Thus, the data were available for 32 patients (66.67%). In
control group, one patient died in the three-month follow-up, and two
patients died in the six-month follow-up. The mortality of the patients
was attributed to heavy head injury. These three patients who died in
control group were inserted in the analysis. In contrast, there was no
mortality in progesterone group (Fig. 1). The demographic and clinical
characteristics of progesterone and control groups in the admission
Table 2
Comparison of the clinical and demographic characteristics between progesterone and
control groups at the admission time.
Characteristics Control
(n = 16)
Progesterone
(n = 16)
P value
Age (years); mean ± SEM 30.75 ± 3.4 28.44 ± 1.74 0.84
Injury time to randomization
(min); mean ± SEM
84.81 ± 9.93 69.36 ± 19.38 0.98
GCS (score); mean ± SEM
Total 7.75 ± 0.52 7.5 ± 0.55 0.81
Moderate 10.4 ± 0.51 10.5 ± 0.87 N0.99
Severe 6.5 ± 0.28 6.5 ± 0.34 0.98
Cause of DAI; n (%): N0.99
Motor vehicle 15 (93.8%) 16 (100%)
Fall 0 (0.0%) 0 (0.0%)
Other 1 (6.2%) 0 (0.0%)
Thedata are also presented as n (%); n: number of patients; GCS: Glasgowcoma scale; DAI:
diffuse axonal injury.
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icantly between the two groups.
3.2. Progesterone effect on outcome
The comparison of the outcome between progesterone and control
groups is shown in Table 3. A quantitative analysis of GOS-E was per-
formed between treatment and control groups. At the admission time,
GOS-E score was not different between the two groups (P = 0.78).
Also, GOS-E score between the two groups was not signiﬁcantly differ-
ent at the three-month follow-up (P = 0.16). But, GOS-E score of the
patients who took progesterone was higher than that in control group
at the six-month follow-up (P b 0.05).
FIM score was not different between the two groups at the admis-
sion time (P = 0.18). Meanwhile, three months after the injury, FIM
score was not different between progesterone and control groups
(P = 0.21). However, higher score of FIM was found in progesterone-
administered DAI patients in comparisonwith control group sixmonths
after the injury (P b 0.01).
A signiﬁcant increase in GCS score was observed in each of proges-
terone and control groups six days after the injury and the discharge
time in comparison to the admission time. There was a signiﬁcant in-
crease in GOS-E and FIM scores in each of progesterone and control
groups at the times of three and six months after the injury in compar-
ison to the admission time. Meanwhile, a signiﬁcant increase in GOS-E
and FIM scores was observed only in progesterone group at the timeTable 3
Comparison of the outcome between progesterone and control groups three and six
months post-DAI.
Outcome Control (n = 16)
mean ± SEM
Progesterone (n = 16)
mean ± SEM
P value
Glasgow outcome scale:
At admission 2.06 ± 0.06 2.00 ± 0.00 0.78
Three months post-trauma 4.5 ± 0.56 5.63 ± 0.54 0.16
Six months post-trauma 5.13 ± 0.68 6.81 ± 0.36 b0.05#
Functional independence measure:
At admission 21.25 ± 0.60 19.56 ± 1.24 0.18
Three months post-trauma 75.00 ± 7.96 88.00 ± 5.38 0.21
Six months post-trauma 69.53 ± 11.42 94.44 ± 4.45 b0.01##
Glasgow coma scale:
At admission 7.75 ± 0.52 7.50 ± 0.55 0.81
Six days post-trauma 10.81 ± 0.97 11.81 ± 0.73 0.54
At discharge 12.92 ± 0.87 13.69 ± 0.44 0.75
n: number of patients; DAI: diffuse axonal injury.
# P b 0.05: signiﬁcant difference between progesterone group and control group six
months after the injury.
## P b 0.01: signiﬁcant difference between progesterone group and control group six
months after the injury.of sixmonths after the injury in comparison to the time of threemonths.
There was no signiﬁcant difference in body temperature, heart and re-
spiratory rates, blood pressure, blood oxygen saturation, and laboratory
testing between progesterone and control groups. No serious adverse
effects were found attributable to the study drug.
3.3. Progesterone effect on serum level of MDA
The effect of progesterone on the serum level ofMDA in DAI patients
is shown in Fig. 2. A signiﬁcant difference in MDA level was not seen
between control and progesterone groups at the time of admission
(P = 0.07). However, 24 h and six days after the injury, a reduction in
MDA level was indicated in progesterone group (0.88 ± 0.23 μmol/mL
and 2.00 ± 0.23 μmol/mL, respectively) compared to control group
(2.56 ± 0.28 and 2.66 ± 0.22 μmol/mL, respectively) (P b 0.001 and
P b 0.05, respectively). MDA reduced in progesterone group compared
to control group 65.62% and 24.66% at 24 h and six days after the injury,
respectively (Fig. 2). There was a signiﬁcant increase in MDA level in
control group at the times of 24 h and six days after the injury compared
to the admission time (P b 0.01). Also, a signiﬁcant decrease in MDA
level in progesterone group was found 24 h after the injury compared
to the times of admission and six days after the injury (P b 0.05).
3.4. Progesterone effect on serum levels of cytokines (IL-1β, IL-6 and TGF-β1)
The effect of progesterone on the serum levels of cytokines in DAI
patients is shown in Fig. 3. The serum level of IL-1β is illustrated in
Fig. 3A. A signiﬁcant difference in IL-1β level was not seen between con-
trol and progesterone groups at the times of admission and six days
after the injury (P = 0.38 and P = 0.23, respectively). But, a reduction
in IL-1β level was revealed in progesterone group (22.62 ±
6.2 pg/mL) in comparison to control group (95.96 ± 30.20 pg/mL)
24 h after the injury (P b 0.05). IL-1β reduced in progesterone group
in comparison to control group 76.42% at 24 h after the injury
(Fig. 3A). A signiﬁcant decrease in IL-1β level was found in progesterone
group during the evaluation in comparison to the admission time
(P b 0.01, at 24 h and six days). Whereas, a signiﬁcant decrease in IL-
1β level was revealed in control group at six days after the injury in
comparison to the times of admission and 24 h after the injury
(P b 0.05).
The effect of progesterone on the serum level of IL-6 in DAI patients
is illustrated in Fig. 3B. A signiﬁcant difference in IL-6 level was not seen
between control and progesterone groups at the times of admission and
six days after the injury (P = 0.85 and P = 0.74, respectively). At 24 hFig. 2. The temporal proﬁle of serum malondialdehyde (MDA) level in progesterone-
administered and control patients with diffuse axonal injury (DAI). The data are
expressed as mean ± SEM. ***P b 0.001 vs. control group at 24 h after the injury;
#P b 0.05 vs. control group at six days after the injury.
Fig. 3. The temporal proﬁle of serum IL-1β, IL-6 and TGF-β1 levels in progesterone-
administered and control patients with diffuse axonal injury (DAI). The data are
expressed as mean ± SEM. A) *P b 0.05 vs. control group at 24 h after the injury.
B) **P b 0.01 vs. control group at 24 h after the injury. C) *P b 0.05 vs. control group at
24 h after the injury; #P b 0.05 vs. control group at six days after the injury.
Fig. 4. The temporal proﬁle of serum S-100B level in progesterone-administered and
control patients with diffuse axonal injury (DAI). The data are expressed as mean ±
SEM. ⁎P b 0.05 vs. control group at 24 h after the injury; #P b 0.05 vs. control group at
six days after the injury.
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gesterone group (58.05 ± 6.50 pg/mL) in comparison with control
group (31.18 ± 5.20 pg/mL) (P b 0.01) that this increase was 86.18%
(Fig. 3B). A signiﬁcant decrease in IL-6 level was found in control
group during the evaluation in comparison with the admission time
(P b 0.01 and P b 0.001, at 24 h and six days, respectively). Furthermore,
signiﬁcant decrease in IL-6 level was observed in progesterone group at
the time of six days after the injury in comparison with the times of ad-
mission and 24 h after the injury (P b 0.01).The effect of progesterone on the serum level of TGF-β1 in DAI
patients is illustrated in Fig. 3C. A signiﬁcant difference in TGF-β1 level
was not seen between control and progesterone groups at the time of
admission (P= 0.29). At 24 h and six days after the injury, a signiﬁcant
increase in TGF-β1 level was found in progesterone group (1474.04 ±
145.18 ng/mL and 1254.54 ± 162.83 ng/mL, respectively) compared
to control group (952.32± 204.25 and 689.85± 162.14 ng/mL, respec-
tively) (P b 0.05) that these increases were 54.8% and 81.78%, respec-
tively (Fig. 3C). A signiﬁcant decrease in TGF-β1 level was observed in
progesterone group at the time of six days after the injury compared
to 24 h after the injury (P b 0.05).
3.5. Progesterone effect on serum level of brain protein (S-100B)
The effect of progesterone on the serum level of S-100B in DAI
patients is shown in Fig. 4. A signiﬁcant difference in S-100B level was
not observed between control and progesterone groups at the time of
admission (P = 0.41). In contrast, 24 h and six days after the injury, a
signiﬁcant decrease in S-100B level was found in progesterone group
(196.38 ± 47.42 pg/mL and 170.53 ± 36.43 pg/mL, respectively) in
comparison with control group (334.47 ± 38.99 and 307.63 ±
50.1 pg/mL, respectively) (P b 0.05). S-100B reduced in progesterone
group compared to control group 41.29% and 44.57% at 24 h and six
days after the injury, respectively (Fig. 4). A signiﬁcant decrease in
S-100B level was revealed in control and progesterone groups during
the evaluation in comparison to the admission time (P b 0.01, at 24 h
and six days).
3.6. Serum level of progesterone
The effect of progesterone on serum level of progesterone in DAI
patients is shown in Table 4. A signiﬁcant difference in progesterone
level was not seen between control and progesterone groups at the
time of admission (P = 0.16). But, progesterone level in patients who
received progesterone was higher than that in control group at 24 h
and six days after the injury (P b 0.001). Unlike control group, a signiﬁ-
cant increase in progesterone level was revealed in progesterone group
during the evaluation compared to admission time (P b 0.05 and
P b 0.001, at 24 h and six days, respectively).
4. Discussion
To our knowledge, the present study is the ﬁrst study to evaluate the
effect of progesterone on the outcome and the serum markers of brain
Table 4
The temporal proﬁle of serum progesterone level in control and progesterone-adminis-
tered patients with DAI.
Serum progesterone level
(ng/mL)
Control (n = 16)
mean ± SEM
Progesterone (n = 16)
mean ± SEM
At admission 12.14 ± 0.94 14.45 ± 1.31
24 h after injury 4.50 ± 0.84 19.42 ± 1.05⁎⁎⁎
Six days after injury 6.55 ± 1.40 20.90 ± 0.56###
n: number of patients; DAI: diffuse axonal injury.
⁎⁎⁎ P b 0.001 vs. control group 24 h after the injury.
### P b 0.001 vs. control group six days after the injury.
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the current study showed that, ﬁrstly, the neurologic outcome (using
GOS-E and FIM) improved in progesterone-administered DAI patients.
Secondly, a modulation in the levels of cytokines (using IL-1β, IL-6
and TGF-β1), and a reduction in oxidant activity (usingMDA) and injury
(S-100B) markers were revealed in these patients. Meanwhile, we ob-
served death cases only in control group. It is necessary to state that
the adverse events attributable to the progesterone administration
were not seen in our research similar to the others [9–11].
In the current research, only TBI patients of DAI type were selected.
Most of the promising therapeutic strategies of the experimental animal
studies have failed in the clinical studies of TBI [45]. And, a human TBI is
a heterogenic disease making it difﬁcult to compare and interpret the
data of the individuals [46]. So, only DAI patients were recruited into
the study tominimize the effects of variations between the TBI patients.
DAI is one of themost common types of TBI [1] and is a progressive pro-
cess initiated by the tensional forces of the injury that gradually results
in early focal axonal alteration and delayed disconnection [47]. Despite
the normal ﬁndings on CT scan, DAI is one of the most serious brain
injuries.
We observed the outcome recovery in progesterone group in the
long term as FIM and GOS-E scores were higher than those in control
group six months after the injury. Interruption of the cascade of the
molecular and cellular responses following the initial impact in TBI
presents an important target to reduce the secondary brain injury.
Meanwhile, TBI is not an event affecting only the brain itself. Regardless
of its etiology, a brain injury has to be considered as a complicated sys-
temic event that affects the function of many organs in addition to the
brain [48]. It seems that multipotential drugs should be considered to
modulate the multiple injury mechanisms in TBI with respect to the
complexity and diversity of the secondary injury mechanisms [6]. Pro-
gesterone has pleiotropic effects that may interrupt the injury cascade
in TBI. And, there are more than 200 articles demonstrating the neuro-
protective effects of progesterone resulting from studies in four species
including humans, and in 22 different brain injurymodels including TBI.
Overall, the preclinical studies have shown that progesterone adminis-
tration results in a reduction in neuronal loss and cerebral edema, and
an improvement in the outcome [7,35,36]. Since there are few clinical
studies investigating the effect of progesterone in TBI while showing
contrary results [9–13], performingmore clinical trials seems necessary.
The results of three single-center clinical trials evaluating the effect
of progesterone on the outcome are in line with our result on the out-
come [9–11]. A reduction in the mortality of progesterone-
administered TBI patients was reported in the research performed by
Xiao et al. and Wright et al. [10,11], but we found the death cases only
in control group. The results of the above investigations suggest the
neuroprotective effect of progesterone in TBI that needs further re-
search to be proved. In contrast, the results of two multicenter clinical
studies evaluating the effect of progesterone are inconsistent with the
result of our study on the outcome [12,13]. The large clinical trials
often failed with no clear reasons, and this failure is not limited to the
trials of TBI [45,49]. Nonetheless, some reasons for these different re-
sults can be proposed including the difference in dose of drug andonset of drug administration, and especially eligibility criteria of studies.
[48]. In addition, there are several models of injury in TBI thatmay have
different pathologic mechanisms with distinct inﬂammatory responses
[46]. Also, different patients may have speciﬁc genetic and epigenetic
histories and respond differently to a similar treatment. Finally, the var-
iability in patients' routine care in different sites, and preexisting condi-
tions and individual characteristics of patients may play a role in the
response to a similar treatment and lead to different results in similar
clinical studies [50,51]. So, dividing the TBI patients in a large clinical
trial into three categories of mild, moderate and severemay not be suit-
able to determine their response to a treatment [48].
Progesterone affects the expression of approximately 500 genes in-
volved in regulating inﬂammation, apoptosis and vascular remodeling
which support the multipotential properties of progesterone [52]. The
multiple neuroprotective mechanisms of progesterone are reduction
of brain edema [53], oxidative stress [29], inﬂammation [33],
excitotoxicity [54], apoptosis and myelin repair [32]. The investigation
of the cellular and biochemical pathways affected by progesterone
shows the reasonable explanation for its efﬁcacy in neuronal injury.
An intact BBB prevents the diffusion of most water-soluble mole-
cules over 500 Da [55]. However, a BBB disruption causes the appear-
ance of brain-related proteins in the systemic circulation [19]. And, the
assessment of TBI biomarkers improves the development of an individ-
ualized treatment [38]. Thus, in the present study, the effect of proges-
terone on both the brain damage and the oxidant activity of DAI
patients was determined by the assay of S-100B and MDA levels in the
serum, respectively. Interestingly, a concomitant reduction of S-100B
and MDA levels was found in progesterone-administered patients
24 h and six days after the injury. The reduction ofMDAby progesterone
has previously been reported in experimental studies in line with our
study [31,56]. But, to the best our knowledge, there has not yet been
any clinical trial assessing the effect of progesterone on S-100B and
MDA biomarkers in TBI.
There is a considerable increase in the production of free radicals in
TBI [23,24], and the brain is greatly vulnerable to injury-induced oxida-
tive damage, so oxidative stress plays a leading role in the pathology of
TBI [57]. Because the direct measurement of free radicals is difﬁcult, an
alternativemethod of the assessment ismeasuring lipid peroxidation by
their products such as MDA [58]. Lipid peroxidation induced by oxida-
tive damage is a phenomenon that induces alterations in cellular
membranes. The highest level of MDA is detected thirty minutes after
brain trauma which is maintained elevated 72 h after the injury onset
[26,59,60]. In the present study, an increase in MDA level was main-
tained in control group during six days of the evaluation. This difference
may be because of the difference in the type of TBI and the time of taking
sample for measurement of MDA in the studies.
S-100Bhas been noticed as an outcomemarker in DAI [20,21]. An in-
crease in S-100Bmay reﬂect either the glial damage or the astrocytes re-
actions to neural injury, referred to as reactive astrogliosis [61,62].
Meanwhile, it has been reported that an increase in serum level of
S-100B is associated with the poor outcome and the extensive brain in-
jury [19,20]. The highest level of S-100B is noticed at the ﬁrst hours of
TBI, and its delayed increase is associated with the secondary brain
damage and the unfavorable outcome [20,21] as the highest level of S-
100Bwas observed at the ﬁrst four hours of injury in our study. In addi-
tion, an increase in S-100B of control group compared to progesterone
group during the evaluation was associated with poor outcome in the
current study. Thus, it is suggested that progesterone may improve
the outcome inDAI at least in part by decreasing oxidant activity leading
to suppressing injury and BBB permeability. However, this requires fur-
ther research.
In the present study, the cytokines levels (IL-1β, IL-6 and TGF-β1)
were measured. Decreasing level of IL-1β and increasing level of IL-6
were indicated in progesterone group 24 h after the injury. A reduction
in progesterone-caused IL-1β has also been reported in experimental
studies [63,64]. BBB abnormalities can be induced by the inﬂammatory
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and the nervous damage resulting fromTBI is inhibited following reduc-
tion of IL-1β [66]. An increase in IL-6 following progesterone adminis-
tration in the current study is in agreement with the study performed
in animal TBI [67]. It has been shown that IL-6 has a dual action both in-
ﬂammatory and anti-inﬂammatory. IL-6 exerts its anti-inﬂammatory
effects via an induction in IL-1Ra (interleukin-1 receptor antagonist)
synthesis and a reduction in TNF-α synthesis [68]. In addition, IL-6
and TNF-α constitute a feedback loop; then TNF-α induces IL-6 produc-
tion, and later IL-6 in turn inhibits TNF-α production. It has been report-
ed that pretreatment with IL-6 reduced the mortality in experimental
septic shock, indication of a protective role of this cytokine [69].
Unlike decreasing in control group, there was increasing level of
TGF-β1 in progesterone-administered patients during our assessment.
The increasing TGF-β1 in progesterone group is in agreement with the
reports of Khaksari et al. and also Gibson et al. in animal TBI [36,64]. It
has been reported that the anti-inﬂammatory actions of TGF-β1 are
dominant, and an anti-inﬂammatory effect of TGF-β1 is probably con-
trolling the production of IL-1β, TNF-α and free radicals of oxygen
[70]. To the best of our knowledge, there has not yet been any clinical
trial assessing the effect of progesterone on cytokines in TBI. Yet, it is
supposed that themodulation of cytokines may be one of other mecha-
nisms of neuroprotective effect of progesterone in the current study.
Further research seems necessary in this respect, though.
Interestingly, unlike a decrease in control group, there is an increase
in the serum level of progesterone in progesterone group during evalu-
ation of the serum markers which is in line with another study [36].
Therefore, it is supposed that changes in the serum level of markers in
progesterone group are attributable to progesterone effect.
In the present research, progesterone group had higher FIM and
GOS-E scores in comparison to control group. Also, this group indicated
a reduction of the serum levels of IL-1β, MDA and S-100B and an eleva-
tion of the serum levels of IL-6, TGF-β1 and progesterone compared to
control.
The authors according to ﬁndings of present study suggest that a free
radical-induced damage to lipids, an increase in IL-1β, and a decrease in
IL-6 and TGF-β1 may be involved in the pathogenesis of the secondary
brain injury of DAI. Also, serum S-100B may be considered as a marker
of this injury. One of ROS sources in TBI can be macrophages/microglia
and neutrophils activated by an inﬂammatory process initiated follow-
ing the initial injury [24]. And, it has been suggested that free radicals
and inﬂammatory cascade may increase BBB permeability leading to
brain edema in TBI [71,72] whereby increasing the serum levels of
S-100B in extensive brain injury [17,19].
The present study has several limitations. First, the number of the
patients in the analyses was small because of selecting only DAI
patients to arrest the heterogeneity of TBI, whereas greater numbers
may demonstrate more differences between the two groups. Second,
the markers were evaluated using serum rather than CSF and paren-
chymal interstitial ﬂuid that disadvantages the investigation due to
the lack of speciﬁcity to the brain tissue and the low sensitivity to
the early injury. Despite these limitations, ﬁrstly, it is the ﬁrst clinical
study investigating the effect of progesterone on the outcome of DAI
patients associated to their serum markers of injury and inﬂamma-
tion. Secondly, we investigated the serummarkers that are rationally
involved in CNS injury including the markers of inﬂammation, injury
and oxidative stress [73].
According to the ﬁndings of the current study, it is suggested that the
outcome recovery in progesterone-administered DAI patients may be
resulted from the neuroprotective effect of progesterone. And, this ef-
fect may be mediated by the anti-inﬂammatory and anti-oxidant prop-
erties of progesterone. Although these ﬁndings are encouraging, further
studies with larger number of patients are needed to decide on the
usage of progesterone therapy. According to the results of this study, ox-
idative stress and inﬂammation seems to be involved in DAI pathogen-
esis. So, further studies are required to better understanding of thedelicate interplay between the cytokine and oxidant response, and the
type of cells that respond to these mediators in TBI.
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